STOCK TITAN

XOMA (XOMA) removes unsold securities after $200M shelf and merger

(Neutral)
Form Type
POS AM

Rhea-AI Filing Summary

XOMA Royalty LLC filed a post-effective amendment to its Form S-3 shelf registration originally covering $200 million of various securities, including unsecured debt, common and preferred stock, depositary shares, subscription rights, contingent value rights, royalty certificates, warrants and units. Following a restructuring in which XOMA Royalty Corporation converted from a Nevada corporation to a Delaware limited liability company and a subsequent merger where Flex Merger Sub, Inc. merged with XOMA Royalty Holdings Corporation to become a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated, all offerings under the shelf have been terminated. This amendment removes from registration all securities that were registered but remained unsold under the S-3 as of the filing date.

Positive

  • None.

Negative

  • None.
Shelf registration size $200 million Amount of securities registered on Form S-3 (File No. 333-277794)
Merger Agreement date April 27, 2026 Date of Agreement and Plan of Merger among XOMA entities and Ligand
Merger completion date July 14, 2026 Date Merger Sub merged with XOMA Royalty Holdings Corporation
Post-effective amendment filing date July 20, 2026 Date the Registrant caused the post-effective amendment to be signed
post-effective amendment regulatory
"This post-effective amendment No. 1 relates to the Registration Statement"
A post-effective amendment is an official update to a securities registration document filed after that document has become effective with regulators; it corrects, adds or replaces information about the securities, the company, or an offering. Investors care because it keeps the legal record current and can change what is being sold or the rights attached to shares — like getting a revised product manual after a launch that may affect value or use.
Registration Statement on Form S-3 regulatory
"relates to the Registration Statement on Form S-3 (File No. 333-277794)"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
Agreement and Plan of Merger regulatory
"pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”)"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Conversion regulatory
"the Registrant converted from a Nevada corporation to a Delaware limited liability company (the “Conversion”)"
Conversion is the exchange of one type of financial instrument for another, most commonly turning convertible bonds or preferred shares into common stock. It matters to investors because conversion changes the number of outstanding shares and ownership stakes—like trading a coupon for a slice of a company—potentially reducing each existing owner's portion, affecting per-share earnings, voting power and the market value of the stock.
royalty certificates financial
"royalty certificates representing the contractual right to receive royalties from the Registrant"
Royalty certificates are tradable claims that give the holder a right to a portion of future payments tied to an asset’s revenue—such as a patent, drug sales, mineral production, or a licensing deal. For investors they act like buying a steady slice of a future cashflow stream: returns depend on how well the underlying asset performs, offering potential income and diversification but also exposure to the asset’s commercial risk.
Offering Type shelf

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does XOMA (XOMA) do in this post-effective amendment?

XOMA Royalty LLC files a post-effective amendment to its Form S-3 to remove from registration all unsold securities that had been registered under a prior $200 million shelf registration.

How large was the original XOMA (XOMA) shelf registration?

The original Form S-3 shelf registration covered $200 million of securities, including unsecured debt, common and preferred stock, depositary shares, subscription rights, contingent value rights, royalty certificates, warrants and units.

Why is XOMA (XOMA) deregistering these securities?

XOMA is deregistering the securities because, following a merger with entities affiliated with Ligand Pharmaceuticals Incorporated, it has terminated all offerings under the Form S-3 shelf registration.

What corporate changes occurred at XOMA (XOMA) before deregistration?

Before deregistration, XOMA Royalty Corporation completed a Conversion from a Nevada corporation to a Delaware limited liability company and then participated in a merger under an Agreement and Plan of Merger dated April 27, 2026.

Which securities types are affected by XOMA (XOMA)'s deregistration?

The deregistration affects all unsold securities previously registered, including unsecured debt securities, common stock, preferred stock, depositary shares, subscription rights, contingent value rights, royalty certificates, warrants and units.

Who is the new parent company in the XOMA (XOMA) merger structure?

After the merger, XOMA Royalty Holdings Corporation became a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated, which is identified as the Parent in the Agreement and Plan of Merger.

As filed with the Securities and Exchange Commission on July 20, 2026.

Registration No. 333-277794

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1

TO

FORM S-3

REGISTRATION STATEMENT NO. 333-277794

UNDER

THE SECURITIES ACT OF 1933

 

 

XOMA ROYALTY LLC

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   52-2154066
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

2200 Powell Street, Suite 310

Emeryville, CA 94608

(510) 204-7200

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

c/o XOMA Royalty LLC

2200 Powell Street, Suite 310

Emeryville, CA 94608

(510) 204-7200

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Approximate date of commencement of proposed sale to the public: Not Applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


DEREGISTRATION OF SECURITIES

This post-effective amendment No. 1 (this “Post-Effective Amendment”) relates to the Registration Statement on Form S-3 (File No. 333-277794) (the “Registration Statement”) originally filed with the Securities and Exchange Commission (the “SEC”) by XOMA Royalty Corporation, a Nevada corporation (the “Registrant”), on March 8, 2024 in respect of $200 million of: (i) the Registrant’s unsecured debt securities (the “Debt Securities”); (ii) shares of the Registrant’s common stock, par value $0.0075 per share (the “Common Stock”); (iii) shares of the Registrant’s preferred stock, par value $0.05 per share (the “Preferred Stock”); (iv) depositary shares each representing a fraction of a share of a particular series of Preferred Stock (the “Depositary Shares”); (v) subscription rights to purchase Common Stock, Preferred Stock, Depositary Shares and/or Debt Securities, (vi) contingent value rights representing the contractual right to receive additional consideration in connection with an acquisition of businesses, assets, royalty interests or securities of other companies; (vii) royalty certificates representing the contractual right to receive royalties from the Registrant and/or the Registrant’s existing or future subsidiaries; (viii) warrants for the purchase of Common Stock, Preferred Stock, Depositary Shares or Debt Securities; and (ix) units of the Registrant comprised of any of the foregoing.

On July 14, 2026, pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 27, 2026, by and among the Registrant, Ligand Pharmaceuticals Incorporated, a Delaware Corporation (“Parent”), Flex Merger Sub, Inc., a Nevada corporation and wholly owned subsidiary of Parent (“Merger Sub”) and XOMA Royalty Holdings Corporation, a Nevada corporation (“HoldCo”), Merger Sub merged with and into HoldCo with HoldCo surviving as a wholly owned subsidiary of Parent (the “Merger”).

Prior to giving effect to the Merger, the Registrant effected a restructuring pursuant to which, among other matters, the Registrant converted from a Nevada corporation to a Delaware limited liability company (the “Conversion”). Reference herein to the “Registrant” refers to (i) “XOMA Royalty Corporation” with respect to matters occurring prior to the effectiveness of the Conversion, and (ii) “XOMA Royalty LLC” with respect to matters occurring on and after the effectiveness of the Conversion.

As a result of the Merger, the Registrant has terminated all offerings of its securities pursuant to the Registration Statement. In accordance with the undertakings made by the Registrant in the Registration Statement to remove from registration, by means of post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, by filing this Post-Effective Amendment, the Registrant hereby removes from registration all securities registered but unsold under the Registration Statement, if any, as of the date hereof.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, on the 20th day of July, 2026.

 

XOMA ROYALTY LLC

 

/s/ Owen Hughes

Name: Owen Hughes
Title: Authorized Person